{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T07:10:17Z","timestamp":1790838617975,"version":"4.1.0"},"reference-count":69,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:00:00Z","timestamp":1778198400000},"content-version":"vor","delay-in-days":127,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Recovery and Resilience Plan, Investment PE8\u2014Project Age-It"},{"name":"\u2018Ageing Well in an Ageing Society\u2019\/Next Generation EU"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Cognitive impairment is a major non-motor feature of Parkinson\u2019s disease (PD). Alzheimer\u2019s disease CSF biomarkers\u2014amyloid-\u03b2 (A\u03b242, A\u03b242\/40), phosphorylated tau (p-tau) and total tau (t-tau)\u2014may influence both cognitive and motor outcomes, but their role in relation to Parkinson\u2019s disease phenotype or progression remains unclear. Moreover, few studies have investigated these associations using extensive neuropsychological batteries. The aim of the study was to examine the associations between CSF Alzheimer\u2019s disease biomarkers, domain-specific neuropsychological performance and motor impairment in Parkinson\u2019s disease and to evaluate their predictive value for longitudinal changes. Seventy-eight Parkinson\u2019s disease patients underwent extensive neuropsychological examination, along with motor evaluation and Alzheimer\u2019s disease CSF biomarkers quantification. Fifty-two patients completed follow-up motor assessment and 43 repeated cognitive evaluation after 18\u201324 months. Correlation and regression models adjusted for demographic and clinical covariates were applied. Thirty-nine patients were classified as mild cognitive impaired (PD-MCI), mostly with multidomain impairment. Amyloid-\u03b2 biomarkers were associated with poorer attention, working memory, executive and language performance. Tau proteins were inversely associated with motor scores. PD-MCI patients tended to experience greater motor decline than cognitive unimpaired subjects. Over time, higher p-tau and t-tau predicted global cognitive decline (MMSE), while lower A\u03b242\/40 predicted worsening in verbal memory and reasoning. Higher t-tau and lower baseline MMSE independently predicted greater motor deterioration. CSF Alzheimer\u2019s disease biomarkers showed domain-specific relationships with cognitive function and predicted both neuropsychological decline and motor progression. Combining detailed neuropsychological profiling with Alzheimer\u2019s disease biomarkers assessment may improve identification of high-risk patients and support integrated biological definitions of Parkinson\u2019s disease.<\/jats:p>","DOI":"10.1093\/braincomms\/fcag166","type":"journal-article","created":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T11:41:11Z","timestamp":1778067671000},"source":"Crossref","is-referenced-by-count":1,"title":["Predictive value of cerebrospinal fluid Alzheimer\u2019s disease biomarkers and neuropsychological measures for cognitive and motor outcomes in Parkinson\u2019s disease"],"prefix":"10.1093","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-2029-6763","authenticated-orcid":false,"given":"Alessandro","family":"Scalese","sequence":"first","affiliation":[{"name":"Neurology Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCCS , Rome 00168 ,","place":["Italy"]},{"name":"Department of Neuroscience, Catholic University of the Sacred Heart , Rome 00168 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7271-1229","authenticated-orcid":false,"given":"Guido Maria","family":"Giuffr\u00e8","sequence":"additional","affiliation":[{"name":"Neurology Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCCS , Rome 00168 ,","place":["Italy"]},{"name":"Department of Neuroscience, Catholic University of the Sacred Heart , Rome 00168 ,","place":["Italy"]},{"name":"Memory Clinic, Fondazione Policlinico Universitario Agostino Gemelli IRCCS , Rome 00168 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2413-1788","authenticated-orcid":false,"given":"Giulia","family":"Di Lazzaro","sequence":"additional","affiliation":[{"name":"Neurology Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCCS , Rome 00168 ,","place":["Italy"]},{"name":"Department of Neuroscience, Catholic University of the Sacred Heart , Rome 00168 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9298-565X","authenticated-orcid":false,"given":"Angelo Tiziano","family":"Cimmino","sequence":"additional","affiliation":[{"name":"Neurology Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCCS , Rome 00168 ,","place":["Italy"]},{"name":"Department of Neuroscience, Catholic University of the Sacred Heart , Rome 00168 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3367-0971","authenticated-orcid":false,"given":"Francesco","family":"Musso","sequence":"additional","affiliation":[{"name":"Neurology Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCCS , Rome 00168 ,","place":["Italy"]},{"name":"Department of Neuroscience, Catholic University of the Sacred Heart , Rome 00168 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Orsini","sequence":"additional","affiliation":[{"name":"Memory Clinic, Fondazione Policlinico Universitario Agostino Gemelli IRCCS , Rome 00168 ,","place":["Italy"]},{"name":"Clinical Psychology, Fondazione Policlinico Universitario A. Gemelli IRCCS , Rome 00618 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2905-6625","authenticated-orcid":false,"given":"Davide","family":"Quaranta","sequence":"additional","affiliation":[{"name":"Neurology Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCCS , Rome 00168 ,","place":["Italy"]},{"name":"Department of Neuroscience, Catholic University of the Sacred Heart , Rome 00168 ,","place":["Italy"]},{"name":"Department of Psychology, Catholic University of the Sacred Heart , Milan 20123 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6547-4990","authenticated-orcid":false,"given":"Maria Gabriella","family":"Vita","sequence":"additional","affiliation":[{"name":"Neurology Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCCS , Rome 00168 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0265-7666","authenticated-orcid":false,"given":"Carla","family":"Piano","sequence":"additional","affiliation":[{"name":"Neurology Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCCS , Rome 00168 ,","place":["Italy"]},{"name":"Department of Neuroscience, Catholic University of the Sacred Heart , Rome 00168 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0326-5509","authenticated-orcid":false,"given":"Paolo","family":"Calabresi","sequence":"additional","affiliation":[{"name":"Neurology Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCCS , Rome 00168 ,","place":["Italy"]},{"name":"Department of Neuroscience, Catholic University of the Sacred Heart , Rome 00168 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3994-4044","authenticated-orcid":false,"given":"Camillo","family":"Marra","sequence":"additional","affiliation":[{"name":"Memory Clinic, Fondazione Policlinico Universitario Agostino Gemelli IRCCS , Rome 00168 ,","place":["Italy"]},{"name":"Department of Psychology, Catholic University of the Sacred Heart , Milan 20123 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9663-095X","authenticated-orcid":false,"given":"Anna Rita","family":"Bentivoglio","sequence":"additional","affiliation":[{"name":"Neurology Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCCS , Rome 00168 ,","place":["Italy"]},{"name":"Department of Neuroscience, Catholic University of the Sacred Heart , Rome 00168 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,7]]},"reference":[{"issue":"4","key":"2026052202063674100_fcag166-B1","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1177\/0891988712464823","article-title":"Cognitive impairment in Parkinson disease: Impact on quality of life, disability, and caregiver burden","volume":"25","author":"Leroi","year":"2012","journal-title":"J Geriatr Psychiatry Neurol"},{"issue":"6","key":"2026052202063674100_fcag166-B2","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1212\/WNL.56.6.730","article-title":"Risk of dementia in Parkinson\u2019s disease: A community-based, prospective study","volume":"56","author":"Aarsland","year":"2001","journal-title":"Neurology"},{"issue":"12","key":"2026052202063674100_fcag166-B3","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1002\/mds.27135","article-title":"Cognitive changes in prodromal Parkinson\u2019s disease: A review","volume":"32","author":"Fengler","year":"2017","journal-title":"Mov Disord Off J Mov Disord Soc"},{"issue":"1","key":"2026052202063674100_fcag166-B4","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/s41582-023-00905-z","article-title":"A multiple hits hypothesis for memory dysfunction in Parkinson disease","volume":"20","author":"Citro","year":"2024","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"2026052202063674100_fcag166-B5","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41572-021-00280-3","article-title":"Parkinson disease-associated cognitive impairment","volume":"7","author":"Aarsland","year":"2021","journal-title":"Nat Rev Dis Primer"},{"issue":"4","key":"2026052202063674100_fcag166-B6","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA Research framework: Toward a biological definition of Alzheimer\u2019s disease","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimers Dement J Alzheimers Assoc"},{"issue":"8","key":"2026052202063674100_fcag166-B7","doi-asserted-by":"crossref","first-page":"5143","DOI":"10.1002\/alz.13859","article-title":"Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s association workgroup","volume":"20","author":"Jack","year":"2024","journal-title":"Alzheimers Dement J Alzheimers Assoc"},{"issue":"7","key":"2026052202063674100_fcag166-B8","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S1474-4422(22)00120-X","article-title":"A biological classification of Huntington\u2019s disease: The integrated staging system","volume":"21","author":"Tabrizi","year":"2022","journal-title":"Lancet Neurol"},{"issue":"10","key":"2026052202063674100_fcag166-B9","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1002\/acn3.338","article-title":"Alpha-synuclein RT-QuIC in the CSF of patients with alpha-synucleinopathies","volume":"3","author":"Fairfoul","year":"2016","journal-title":"Ann Clin Transl Neurol"},{"issue":"1","key":"2026052202063674100_fcag166-B10","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s00401-020-02160-8","article-title":"Ultrasensitive RT-QuIC assay with high sensitivity and specificity for Lewy body-associated synucleinopathies","volume":"140","author":"Rossi","year":"2020","journal-title":"Acta Neuropathol."},{"issue":"6","key":"2026052202063674100_fcag166-B11","doi-asserted-by":"crossref","DOI":"10.3390\/clinpract15060107","article-title":"Alpha-synuclein seed amplification assays in Parkinson\u2019s disease: A systematic review and network meta-analysis","volume":"15","author":"Rissardo","year":"2025","journal-title":"Clin Pract"},{"issue":"6","key":"2026052202063674100_fcag166-B12","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1038\/s41591-023-02358-9","article-title":"Propagative \u03b1-synuclein seeds as serum biomarkers for synucleinopathies","volume":"29","author":"Okuzumi","year":"2023","journal-title":"Nat Med"},{"issue":"2","key":"2026052202063674100_fcag166-B13","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/S1474-4422(23)00405-2","article-title":"A biological definition of neuronal \u03b1-synuclein disease: Towards an integrated staging system for research","volume":"23","author":"Simuni","year":"2024","journal-title":"Lancet Neurol"},{"issue":"2","key":"2026052202063674100_fcag166-B14","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S1474-4422(23)00404-0","article-title":"A biological classification of Parkinson\u2019s disease: The SynNeurGe research diagnostic criteria","volume":"23","author":"H\u00f6glinger","year":"2024","journal-title":"Lancet Neurol"},{"issue":"2","key":"2026052202063674100_fcag166-B15","doi-asserted-by":"crossref","DOI":"10.3390\/brainsci11020215","article-title":"Cerebrospinal fluid biomarkers of Alzheimer\u2019s disease: Current evidence and future perspectives","volume":"11","author":"McGrowder","year":"2021","journal-title":"Brain Sci"},{"issue":"2","key":"2026052202063674100_fcag166-B16","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/mds.27232","article-title":"Cerebrospinal fluid, plasma, and saliva in the BioFIND study: Relationships among biomarkers and Parkinson\u2019s disease features","volume":"33","author":"Goldman","year":"2018","journal-title":"Mov Disord"},{"issue":"20","key":"2026052202063674100_fcag166-B17","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1212\/WNL.0000000000000425","article-title":"CSF A\u03b242 predicts early-onset dementia in Parkinson disease","volume":"82","author":"Alves","year":"2014","journal-title":"Neurology"},{"issue":"2","key":"2026052202063674100_fcag166-B18","doi-asserted-by":"crossref","DOI":"10.3390\/biom12020329","article-title":"Update on CSF biomarkers in Parkinson\u2019s disease","volume":"12","author":"Kwon","year":"2022","journal-title":"Biomolecules"},{"issue":"6","key":"2026052202063674100_fcag166-B19","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S1474-4422(19)30024-9","article-title":"CSF and blood biomarkers for Parkinson\u2019s disease","volume":"18","author":"Parnetti","year":"2019","journal-title":"Lancet Neurol"},{"issue":"1","key":"2026052202063674100_fcag166-B20","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/s41531-023-00509-w","article-title":"CSF neurochemical profile and cognitive changes in Parkinson\u2019s disease with mild cognitive impairment","volume":"9","author":"Paolini Paoletti","year":"2023","journal-title":"NPJ Park Dis"},{"issue":"12","key":"2026052202063674100_fcag166-B21","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/mds.26424","article-title":"MDS clinical diagnostic criteria for Parkinson\u2019s disease","volume":"30","author":"Postuma","year":"2015","journal-title":"Mov Disord Off J Mov Disord Soc"},{"key":"2026052202063674100_fcag166-B22","author":"The Unified Parkinson\u2019s Disease Rating Scale (UPDRS): status and recommendations\u2014PubMed"},{"issue":"9","key":"2026052202063674100_fcag166-B23","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/mds.20213","article-title":"Movement disorder society task force report on the Hoehn and Yahr staging scale: Status and recommendations","volume":"19","author":"Goetz","year":"2004","journal-title":"Mov Disord Off J Mov Disord Soc"},{"issue":"3","key":"2026052202063674100_fcag166-B24","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","article-title":"Mini-mental state\u201d. A practical method for grading the cognitive state of patients for the clinician","volume":"12","author":"Folstein","year":"1975","journal-title":"J Psychiatr Res"},{"issue":"6","key":"2026052202063674100_fcag166-B25","first-page":"378","article-title":"The mental deterioration battery: Normative data, diagnostic reliability and qualitative analyses of cognitive impairment. The group for the standardization of the mental deterioration battery","volume":"36","author":"Carlesimo","year":"1996","journal-title":"Eur Neurol"},{"issue":"3","key":"2026052202063674100_fcag166-B26","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/mds.24893","article-title":"Diagnostic criteria for mild cognitive impairment in Parkinson\u2019s disease: Movement disorder society task force guidelines","volume":"27","author":"Litvan","year":"2012","journal-title":"Mov Disord Off J Mov Disord Soc"},{"issue":"5","key":"2026052202063674100_fcag166-B27","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1007\/s10072-012-1130-x","article-title":"Forward and backward span for verbal and visuo-spatial data: Standardization and normative data from an Italian adult population","volume":"34","author":"Monaco","year":"2013","journal-title":"Neurol Sci"},{"key":"2026052202063674100_fcag166-B28","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/978-1-4615-0153-4_11","volume-title":"Handbook of nonverbal assessment","author":"John","year":"2003"},{"issue":"4","key":"2026052202063674100_fcag166-B29","first-page":"111","article-title":"A short version of the Stroop test: Normative data in an Italian population sample","volume":"12","author":"Caffarra","year":"2002;","journal-title":"Nuova Rivista di Neurologia"},{"issue":"5","key":"2026052202063674100_fcag166-B30","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1038\/nprot.2006.390","article-title":"Administration and interpretation of the trail making test","volume":"1","author":"Bowie","year":"2006","journal-title":"Nat Protoc"},{"issue":"6","key":"2026052202063674100_fcag166-B31","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s100720200003","article-title":"Rey-osterrieth complex figure: Normative values in an Italian population sample","volume":"22","author":"Caffarra","year":"2002","journal-title":"Neurol Sci"},{"issue":"6","key":"2026052202063674100_fcag166-B32","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1002\/1097-4679(199311)49:6<883::AID-JCLP2270490616>3.0.CO;2-6","article-title":"Rey auditory-verbal learning test: Structure analysis","volume":"49","author":"Vakil","year":"1993","journal-title":"J Clin Psychol"},{"issue":"2","key":"2026052202063674100_fcag166-B33","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s10072-012-0975-3","article-title":"The multiple features target cancellation (MFTC): An attentional visual conjunction search test. Normative values for the Italian population","volume":"34","author":"Marra","year":"2013","journal-title":"Neurol Sci"},{"issue":"9","key":"2026052202063674100_fcag166-B34","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1002\/alz.12316","article-title":"The Alzheimer\u2019s association international guidelines for handling of cerebrospinal fluid for routine clinical measurements of amyloid \u03b2 and tau","volume":"17","author":"Hansson","year":"2021","journal-title":"Alzheimers Dement J Alzheimers Assoc"},{"issue":"1","key":"2026052202063674100_fcag166-B35","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s13195-019-0550-8","article-title":"Clinical validation of the Lumipulse G cerebrospinal fluid assays for routine diagnosis of Alzheimer\u2019s disease","volume":"11","author":"Leit\u00e3o","year":"2019","journal-title":"Alzheimers Res Ther"},{"key":"2026052202063674100_fcag166-B36","first-page":"99","article-title":"Domain specific cognitive impairment in Parkinson\u2019s patients with mild cognitive impairment","volume":"75","author":"Chaudhary","year":"2020","journal-title":"J Clin Neurosci Off J Neurosurg Soc Australas"},{"issue":"1","key":"2026052202063674100_fcag166-B37","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s40035-017-0094-4","article-title":"Mild cognitive impairment in Parkinson\u2019s disease: A distinct clinical entity?","volume":"6","author":"Wen","year":"2017","journal-title":"Transl Neurodegener"},{"issue":"1","key":"2026052202063674100_fcag166-B38","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/mds.27902","article-title":"Prevalence and clinical aspects of mild cognitive impairment in Parkinson\u2019s disease: A meta-analysis","volume":"35","author":"Baiano","year":"2020","journal-title":"Mov Disord Off J Mov Disord Soc"},{"issue":"1","key":"2026052202063674100_fcag166-B39","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s11065-021-09502-7","article-title":"Meta-analysis of cognition in Parkinson\u2019s disease mild cognitive impairment and dementia progression","volume":"32","author":"Wallace","year":"2022","journal-title":"Neuropsychol Rev"},{"issue":"5","key":"2026052202063674100_fcag166-B40","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1002\/mds.30166","article-title":"Neuropsychological tests of memory, visuospatial, and language function in Parkinson\u2019s disease: Review, critique, and recommendations","volume":"40","author":"Bezdicek","journal-title":"Mov Disord"},{"issue":"5","key":"2026052202063674100_fcag166-B41","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0303644","article-title":"Machine learning for the detection and diagnosis of cognitive impairment in Parkinson\u2019s disease: A systematic review","volume":"19","author":"Altham","year":"2024","journal-title":"PLoS One"},{"issue":"3","key":"2026052202063674100_fcag166-B42","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1159\/000094871","article-title":"Beta-amlyoid 1-42 and tau-protein in cerebrospinal fluid of patients with Parkinson\u2019s disease dementia","volume":"22","author":"Mollenhauer","year":"2006","journal-title":"Dement Geriatr Cogn Disord"},{"key":"2026052202063674100_fcag166-B43","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2019.00391","article-title":"Beta amyloid deposition is not associated with cognitive impairment in Parkinson\u2019s disease","volume":"10","author":"Melzer","year":"2019","journal-title":"Front Neurol"},{"issue":"3","key":"2026052202063674100_fcag166-B44","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s00401-015-1526-9","article-title":"Pathological \u03b1-synuclein distribution in subjects with coincident Alzheimer\u2019s and Lewy body pathology","volume":"131","author":"Toledo","year":"2016","journal-title":"Acta Neuropathol."},{"issue":"11","key":"2026052202063674100_fcag166-B45","first-page":"1234","article-title":"Neuropathology of dementia in patients with Parkinson\u2019s disease: A systematic review of autopsy studies","volume":"90","author":"Smith","year":"2019","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"2026052202063674100_fcag166-B46","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1136\/jnnp-2012-303808","article-title":"Cerebrospinal fluid amyloid-\u03b2 and phenotypic heterogeneity in de novo Parkinson\u2019s disease","volume":"84","author":"Alves","year":"2013","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"10","key":"2026052202063674100_fcag166-B47","first-page":"1277","article-title":"Association of cerebrospinal fluid \u03b2-amyloid 1-42, T-tau, P-tau181, and \u03b1-synuclein levels with clinical features of drug-naive patients with early Parkinson disease","volume":"70","author":"Kang","year":"2013","journal-title":"JAMA Neurol"},{"issue":"3","key":"2026052202063674100_fcag166-B48","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1002\/mds.25213","article-title":"\u03b2-Amyloid and postural instability and gait difficulty in Parkinson\u2019s disease at risk for dementia","volume":"28","author":"M\u00fcller","year":"2013","journal-title":"Mov Disord Off J Mov Disord Soc"},{"issue":"11","key":"2026052202063674100_fcag166-B49","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1007\/s00415-018-9100-8","article-title":"Amyloid-\u03b2 and Parkinson\u2019s disease","volume":"266","author":"Lim","year":"2019","journal-title":"J Neurol"},{"issue":"1","key":"2026052202063674100_fcag166-B50","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1212\/WNL.0000000000001098","article-title":"CSF biomarkers and clinical progression of Parkinson disease","volume":"84","author":"Hall","year":"2015","journal-title":"Neurology"},{"issue":"6","key":"2026052202063674100_fcag166-B51","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1002\/mds.26578","article-title":"Longitudinal measurements of cerebrospinal fluid biomarkers in Parkinson\u2019s disease","volume":"31","author":"Hall","year":"2016","journal-title":"Mov Disord"},{"issue":"5","key":"2026052202063674100_fcag166-B52","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s00401-013-1121-x","article-title":"Longitudinal assessment of tau and amyloid beta in cerebrospinal fluid of Parkinson disease","volume":"126","author":"Zhang","year":"2013","journal-title":"Acta Neuropathol."},{"issue":"1","key":"2026052202063674100_fcag166-B53","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s00415-024-12856-6","article-title":"Cerebrospinal fluid tau and disease progression in early Parkinson\u2019s disease: An 8-year longitudinal study","volume":"272","author":"Xu","year":"2024","journal-title":"J Neurol"},{"issue":"1","key":"2026052202063674100_fcag166-B54","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0006-8993(99)01848-X","article-title":"Cellular co-localization of phosphorylated tau- and NACP\/\u03b1-synuclein-epitopes in Lewy bodies in sporadic Parkinson\u2019s disease and in dementia with Lewy bodies","volume":"843","author":"Arima","year":"1999","journal-title":"Brain Res"},{"issue":"4","key":"2026052202063674100_fcag166-B55","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1093\/jnen\/62.4.389","article-title":"Colocalization of tau and alpha-synuclein epitopes in Lewy bodies","volume":"62","author":"Ishizawa","year":"2003","journal-title":"J Neuropathol Exp Neurol"},{"issue":"11","key":"2026052202063674100_fcag166-B56","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1007\/s12031-020-01776-5","article-title":"Tau in the pathophysiology of Parkinson\u2019s disease","volume":"71","author":"Pan","year":"2021","journal-title":"J Mol Neurosci"},{"issue":"10","key":"2026052202063674100_fcag166-B57","doi-asserted-by":"crossref","first-page":"3454","DOI":"10.1093\/brain\/awac171","article-title":"Tau accelerates \u03b1-synuclein aggregation and spreading in Parkinson\u2019s disease","volume":"145","author":"Pan","year":"2022","journal-title":"Brain J Neurol"},{"key":"2026052202063674100_fcag166-B58","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.semcdb.2018.05.005","article-title":"The interaction of \u03b1-synuclein and tau: A molecular conspiracy in neurodegeneration?","volume":"99","author":"Yan","year":"2020","journal-title":"Semin Cell Dev Biol"},{"key":"2026052202063674100_fcag166-B59","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/978-3-030-51140-1_11","volume-title":"Frontotemporal dementias\u202f: Emerging milestones of the 21st century","author":"Coughlin","year":"2021"},{"issue":"15","key":"2026052202063674100_fcag166-B60","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1002\/mds.22594","article-title":"Cerebrospinal tau, phospho-tau, and beta-amyloid and neuropsychological functions in Parkinson\u2019s disease","volume":"24","author":"Compta","year":"2009","journal-title":"Mov Disord Off J Mov Disord Soc"},{"issue":"1","key":"2026052202063674100_fcag166-B61","doi-asserted-by":"crossref","first-page":"14820","DOI":"10.1038\/s41598-021-94345-8","article-title":"Temporal trajectory of biofluid markers in Parkinson\u2019s disease","volume":"11","author":"Baek","year":"2021","journal-title":"Sci Rep"},{"issue":"7","key":"2026052202063674100_fcag166-B62","article-title":"The role of alpha-synuclein and tubulin-associated unit (tau) proteins in the diagnosis, prognosis, and treatment of Parkinson\u2019s disease: A systematic review","volume":"16","author":"Lin","year":"2024","journal-title":"Cureus"},{"issue":"12","key":"2026052202063674100_fcag166-B63","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1212\/WNL.0b013e3181f39a78","article-title":"CSF amyloid {beta} 1-42 predicts cognitive decline in Parkinson disease","volume":"75","author":"Siderowf","year":"2010","journal-title":"Neurology"},{"issue":"8","key":"2026052202063674100_fcag166-B64","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.parkreldis.2013.03.009","article-title":"Combined dementia-risk biomarkers in Parkinson\u2019s disease: A prospective longitudinal study","volume":"19","author":"Compta","year":"2013","journal-title":"Parkinsonism Relat Disord"},{"issue":"1","key":"2026052202063674100_fcag166-B65","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/S1474-4422(16)30328-3","article-title":"Clinical variables and biomarkers in prediction of cognitive impairment in patients with newly diagnosed Parkinson\u2019s disease: A cohort study","volume":"16","author":"Schrag","year":"2017","journal-title":"Lancet Neurol"},{"issue":"2","key":"2026052202063674100_fcag166-B66","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1136\/jnnp-2018-318956","article-title":"Parkinson\u2019s disease: Evolution of cognitive impairment and CSF A\u03b21\u201342 profiles in a prospective longitudinal study","volume":"90","author":"Lerche","year":"2019","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"2026052202063674100_fcag166-B67","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.parkreldis.2014.12.027","article-title":"CSF tau and tau\/A\u03b242 predict cognitive decline in Parkinson\u2019s disease","volume":"21","author":"Liu","year":"2015","journal-title":"Parkinsonism Relat Disord"},{"issue":"4","key":"2026052202063674100_fcag166-B68","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1001\/jamaneurol.2022.5272","article-title":"Prediction of longitudinal cognitive decline in preclinical Alzheimer disease using plasma biomarkers","volume":"80","author":"Mattsson-Carlgren","year":"2023","journal-title":"JAMA Neurol"},{"issue":"5","key":"2026052202063674100_fcag166-B69","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1136\/jnnp-2014-310095","article-title":"Risk factors for predicting progression from mild cognitive impairment to Alzheimer\u2019s disease: A systematic review and meta-analysis of cohort studies","volume":"87","author":"Li","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"}],"container-title":["Brain Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/braincomms\/advance-article-pdf\/doi\/10.1093\/braincomms\/fcag166\/68247965\/fcag166.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/braincomms\/article-pdf\/8\/3\/fcag166\/68247965\/fcag166.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/braincomms\/article-pdf\/8\/3\/fcag166\/68247965\/fcag166.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T06:06:49Z","timestamp":1779430009000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/braincomms\/article\/doi\/10.1093\/braincomms\/fcag166\/8672707"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":69,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5,5]]}},"URL":"https:\/\/doi.org\/10.1093\/braincomms\/fcag166","relation":{},"ISSN":["2632-1297"],"issn-type":[{"value":"2632-1297","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026]]},"published":{"date-parts":[[2026]]},"article-number":"fcag166"}}